ADIPEARL
LIVE

Serial Number

98610045

Owner

Volumina Medical SA

Attorney

Amy C. Ziegler

Filing Date

Jun 20, 2024

Add to watchlist:

No watchlists yet
View on USPTO

ADIPEARL Trademark

Serial Number: 98610045 • Registration: 8073554

ADIPEARL is a trademark filed by Volumina Medical SA on June 20, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Volumina Medical SA

Route de la Corniche 5
Epalinges 1066 , CH

Entity Type: 99

Trademark Details

Filing Date

June 20, 2024

Registration Date

December 23, 2025

Published for Opposition

November 4, 2025

Goods & Services

Pharmaceutical preparations, in particular for tissue enhancement and reconstruction, for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours in dermatology for aesthetic medicine, for reconstructive medicine and for reconstructive surgery; medical and veterinary preparations and articles, in particular medical and veterinary preparations for treating the loss of soft tissue volume as well as for improving skin quality and volume contours in dermatology for tissue enhancement and reconstruction; pre-filled syringes filled with pharmaceutical preparations for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours in dermatology for medical purposes; Pre-filled vials filled with pharmaceutical preparations for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours in dermatology for medical and aesthetic medicine purposes; vials and syringes, pre-filled with a medical preparation for enabling cellular or tissular assembly for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours in dermatology for aesthetic and medical purposes; injectable dermal fillers; biological implants, namely, implants comprising living tissue; implantable medicines for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours in dermatology; injectable materials in the nature of injectable gels for treating the loss of soft tissue volume in humans for tissue repair, enhancement, creation or regeneration; implantable materials in the nature of injectable gels for treating the loss of soft tissue volume in humans containing an anaesthetic agent or a pharmaceutical ingredient; injectable materials in the nature of injectable gels for treating the loss of soft tissue volume in humans containing an anaesthetic agent or a pharmaceutical ingredient; none of the aforementioned in relation to medication and drugs for preventing, curing or slowing down the progression of cancer; polysaccharide compositions in the nature of injectable gels for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours in dermatology for use in the dermal filler industry; polymeric biomaterials, in particular polymeric biomaterials in the nature of injectable gels for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours in dermatology for use in the cell therapy industry; injectable biomaterials in the nature of injectable gels for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours in dermatology, in particular for use in aesthetic medicine, aesthetic surgery, reconstructive surgery; injectable biomaterials in the nature of injectable gels for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours in dermatology in the form of microgels; injectable biomaterials in the nature of injectable gels for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours in dermatology in the form of particles, in the form of paste or putty, in the form of a dry material; implantable biomaterials in the nature of pharmaceutical preparations for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours, in particular for enhancing or creating new skin volumes or skin layers, in the form of three-dimensional volumes; injectable biocompatible material in the nature of injectable gels for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours, in particular for enhancing or creating new skin volumes or skin layers, in dermatology used for tissues in particular soft tissues

Chemical polymers for use in the manufacture of pharmaceutical preparations and medical implants; biodegradable polymer compositions for use in the manufacture of pharmaceutical preparations and medical implants

Surgical apparatus and instruments; prosthetic and filling materials, namely artificial materials for use in the replacement of soft tissue in humans, and artificial implants; artificial breast implants; medical implants made of artificial materials; biodegradable implants consisting of artificial materials; scaffolding material for the use of three-dimensional shapeable body implants, namely, implantable scaffolds comprising artificial materials for creating new tissue volume or to compensate for tissue volume loss and serving as a scaffold for the regeneration of human tissue; artificial materials for the repair and enhancement of human tissue, namely, implantable scaffolds comprising artificial materials for creating new tissue volume or to compensate for tissue volume loss and serving as a scaffold for the regeneration of human tissue; suture materials; syringes for injections; syringes, vials, containers and sterile bags sold together as medical apparatus for preparing a cellular or tissular construct, for preparing a pharmaceutical composition, and for mixing the composition with an anesthetic agent for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours, in particular for enhancing or creating new skin volumes or skin layers in dermatology or plastic surgery for use in the dermal filler industry or tissue reconstruction and enhancement industry, or in the regenerative medicine industry; medical injection syringes; syringes for medical use; medical syringes for use in aesthetic surgery, in particular, in dermatology and reconstructive surgery; pharmaceutical implants made of artificial materials; implants made of artificial materials for guided tissue regeneration.

Filing History

NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
May 19, 2026 NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
May 19, 2026 NURC
CORRECTION UNDER SECTION 7 - PROCESSED
Apr 27, 2026 COC.
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 27, 2026 APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 17, 2026 APRE
TEAS SECTION 7 REQUEST RECEIVED
Jan 15, 2026 ES7R
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 23, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 23, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 4, 2025 NPUB
PUBLISHED FOR OPPOSITION
Nov 4, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 29, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 2, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 15, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 15, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 15, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 15, 2025 CNEA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jul 10, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jul 10, 2025 XELR
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Apr 15, 2025 GEAN
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Apr 15, 2025 GEAP
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
Apr 15, 2025 EPEN
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Apr 15, 2025 CPEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 27, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 27, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 27, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 14, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jan 14, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jan 14, 2025 CNRT
ASSIGNED TO EXAMINER
Jan 14, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 13, 2025 NWOS
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 24, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Sep 24, 2024 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 24, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 24, 2024 REAP
NEW APPLICATION ENTERED
Jun 20, 2024 NWAP